Entering text into the input field will update the search result below

Sunesis advancing blood cancer candidate vecabrutinib

Jan. 02, 2019 9:21 AM ETViracta Therapeutics, Inc. (VIRX) StockBy: Douglas W. House, SA News Editor
  • Sunesis Pharmaceuticals (SNSS) opens the 100 mg cohort in its Phase 1b/2 clinical trial evaluating BTK inhibitor vecabrutinib in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell blood cancers.
  • Data on the 50 mg group were presented at ASH last month.
  • The company expects the target dose will be between 100 mg and 300 mg twice daily.
  • Updated data will be presented at a major medical meeting next quarter.
  • Previously: Sunesis Pharma down 34% on vecabrutinib data (Dec. 3, 2018)

Recommended For You

More Trending News

About VIRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VIRX--
Viracta Therapeutics, Inc.